The DOI matches its Crossref record.
The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
Open accessAbstract
Summary: Because of its B‐cell depleting effect, rituximab has entered clinical trials in several autoimmune conditions. This study assesses the efficacy and safety of rituximab in 57 adults with chronic immune thrombocytopenic purpura (ITP). All patients had platelet counts <30 × 10 9/l, all had received two or more previous ITP treatments and 31 had undergone splenectomy. Patients received rituximab 375 mg/m 2 weekly for 4 weeks. Thirty‐one patients (54%) responded, achieving a platelet count >50 × 10 9/l: 18 achieved a complete response (CR: platelet count >150 × 10 9/l) and 13 a partial response (PR: platelet count 50–150 × 10 9/l). Twenty‐nine responses occurred within 8 weeks of the first infusion. Sixteen of 18 CR patients (28% overall), including eight who had failed splenectomy, continued in CR after a median of 72·5 weeks; 15 of 16 are >1 year from the first infusion. Only two of 13 maintained a PR. Thirty‐three patients experienced grade 1–2 adverse events and one a grade 3 event, but they all completed treatment. Circulating B cells fell to <0·03 × 10 9/l. No changes in immunoglobulin levels or infectious complications were seen. In summary, rituximab was well tolerated with no immediate complications and induced a lasting, substantial response in 32% of adults with chronic ITP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D. M., Bussel, J. B., Cines, D. B., Chong, B. H., Cooper, N., et al. (2009) · Blood · doi:10.1182/blood-2008-07-162503 · Cited by 2,690
Self-citationProvan, D., Stasi, R., Newland, A. C., Blanchette, V. S., Bolton-Maggs, P., Bussel, J. B., Chong, B. H., Cines, D. B., Gernsheimer, T. B., Godeau, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225565 · Cited by 2,271
Self-citationUpdate on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination
Lee, E., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., Semple, J. W., Arnold, D. M., Godeau, B., Lambert, M. P., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26132 · Cited by 388
Self-citation
Metadata
- Authors
- Cooper, N., Stasi, R., Cunningham‐Rundles, S., Feuerstein, M. A., Leonard, J. P., Amadori, S., & Bussel, J. B.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2004-03-23
- Volume
- 125
- Issue
- 2
- Pages
- 232-239
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2052970048
- Cited by
- 336
- References
- 0
- FWCI
- 21.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. https://app.cochat.ai/papers/10.1111/j.1365-2141.2004.04889.x
- The paper
- Cooper, N., Stasi, R., Cunningham‐Rundles, S., Feuerstein, M. A., Leonard, J. P., Amadori, S., & Bussel, J. B. (2004). The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2004.04889.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.